New drug combo aims to boost immune System's fight against advanced cancers

NCT ID NCT07276373

Recruiting now Disease control Sponsor: Corcept Therapeutics Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and best dose of a new oral drug called nenocorilant when given alongside an established immunotherapy drug (nivolumab) for people with advanced solid tumors. The goal is to see if this combination can help control cancer growth. The study will enroll about 50 adults whose cancers have progressed despite standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site 01
RECRUITING

San Antonio, Texas, 78229, United States
Site 02
RECRUITING

West Valley City, Utah, 84119, United States
Site 03
RECRUITING

Los Angeles, California, 90025, United States
Site 04
RECRUITING

Grand Rapids, Michigan, 49546, United States

Conditions

Explore the condition pages connected to this study.

NEOPLASMS